Skip to main content
Erschienen in: Breast Cancer Research 1/1999

01.12.1999 | Review

The pathology of familial breast cancer: Clinical and geneticcounselling implications of breast cancer pathology

verfasst von: Fiona Lalloo, D Gareth R Evans

Erschienen in: Breast Cancer Research | Ausgabe 1/1999

Einloggen, um Zugang zu erhalten

Abstract

Approximately 5% of all breast cancers are due to one of the high-risk breast cancer genes BRCA1 and BRCA2, or possibly to a third or fourth moderate- to high-risk gene(s). A further proportion of cases arise in the presence of a less striking family history, with later average age at onset and lower penetrance: familial breast cancer. Bilaterality is a recognized feature of hereditary breast cancer. Cancers often present at an early age, with the contralateral risk high within 10 years. Proof that bilateral malignancies are separate primaries can be difficult histologically, however, especially within 3 years. The recent finding of specific pathological features related to BRCA1 and, to a lesser extent, BRCA2 mutations means that, in addition to bilaterality and family history, a pathological element can be entered into the risk calculation for the presence of BRCA1/BRCA2 mutations. This will facilitate the targeting of mutation testing to families in which a positive result is most likely, and may subsequently influence the clinical management of these families.
Literatur
1.
Zurück zum Zitat Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol. 1990, 131: 961-972.PubMed Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol. 1990, 131: 961-972.PubMed
2.
Zurück zum Zitat Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995, 57: 1457-1462.PubMedPubMedCentral Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995, 57: 1457-1462.PubMedPubMedCentral
3.
Zurück zum Zitat Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996, 334: 137-142. 10.1056/NEJM199601183340301.CrossRefPubMed Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996, 334: 137-142. 10.1056/NEJM199601183340301.CrossRefPubMed
4.
5.
Zurück zum Zitat Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial cancer to chromosme 17q21. Science. 1990, 250: 1684-1689.CrossRefPubMed Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial cancer to chromosme 17q21. Science. 1990, 250: 1684-1689.CrossRefPubMed
6.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed
7.
Zurück zum Zitat Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-2090.CrossRefPubMed Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-2090.CrossRefPubMed
8.
Zurück zum Zitat Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer gene BRCA2. Nature. 1995, 378: 789-791. 10.1038/378789a0.CrossRefPubMed Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer gene BRCA2. Nature. 1995, 378: 789-791. 10.1038/378789a0.CrossRefPubMed
10.
Zurück zum Zitat Boyle JM, Greaves MJ, Camplejohn RS, et al: Radiation induced G(1) arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer. 1999, 79: 1657-1664. 10.1038/sj.bjc.6690265.CrossRefPubMedPubMedCentral Boyle JM, Greaves MJ, Camplejohn RS, et al: Radiation induced G(1) arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer. 1999, 79: 1657-1664. 10.1038/sj.bjc.6690265.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Marsh DJ, Coulon V, Lunetta KL, et al: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutations. Hum Mol Genet. 1998, 7: 507-516. 10.1093/hmg/7.3.507.CrossRefPubMed Marsh DJ, Coulon V, Lunetta KL, et al: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutations. Hum Mol Genet. 1998, 7: 507-516. 10.1093/hmg/7.3.507.CrossRefPubMed
12.
Zurück zum Zitat Hemminki A, Markie D, Tomlinson I, et al: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998, 391: 184-187. 10.1038/34432.CrossRefPubMed Hemminki A, Markie D, Tomlinson I, et al: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998, 391: 184-187. 10.1038/34432.CrossRefPubMed
13.
Zurück zum Zitat Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Armes JE, Egan AJM, Southey MC, et al: The histologic phenotypes of breast carcinoma occuring before age 40 years in women with and without BRCA1 and BRCA2 germline mutations. Cancer. 1998, 83: 2335-2345. 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E.CrossRefPubMed Armes JE, Egan AJM, Southey MC, et al: The histologic phenotypes of breast carcinoma occuring before age 40 years in women with and without BRCA1 and BRCA2 germline mutations. Cancer. 1998, 83: 2335-2345. 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E.CrossRefPubMed
15.
Zurück zum Zitat Breast Cancer Linkage Consortium : Pathology of familial breast cancer: differences between cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997, 349: 1505-1510. 10.1016/S0140-6736(96)10109-4.CrossRef Breast Cancer Linkage Consortium : Pathology of familial breast cancer: differences between cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997, 349: 1505-1510. 10.1016/S0140-6736(96)10109-4.CrossRef
16.
Zurück zum Zitat Skolnick MH, Cannon-Albright L, Goldgar DE, et al: Inheritance of proliferative breast disease in breast cancer kindreds. Science. 1990, 250: 1715-1720.CrossRefPubMed Skolnick MH, Cannon-Albright L, Goldgar DE, et al: Inheritance of proliferative breast disease in breast cancer kindreds. Science. 1990, 250: 1715-1720.CrossRefPubMed
17.
Zurück zum Zitat Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312: 146-151.CrossRefPubMed Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312: 146-151.CrossRefPubMed
18.
Zurück zum Zitat Porter DE, Cohen BB, Wallace MR, et al: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation families linked to BRCA1 on chromosome 17q12-21. Br J Surg . 1994, 81: 1512-1515.CrossRefPubMed Porter DE, Cohen BB, Wallace MR, et al: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation families linked to BRCA1 on chromosome 17q12-21. Br J Surg . 1994, 81: 1512-1515.CrossRefPubMed
19.
Zurück zum Zitat Foulkes W, Wong N, Brunet JS, et al: Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997, 3: 2465-2469.PubMed Foulkes W, Wong N, Brunet JS, et al: Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997, 3: 2465-2469.PubMed
20.
Zurück zum Zitat Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998, 351: 316-321. 10.1016/S0140-6736(97)07065-7.CrossRefPubMed Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998, 351: 316-321. 10.1016/S0140-6736(97)07065-7.CrossRefPubMed
21.
Zurück zum Zitat Marcus JN, Watson P, Page DL: Hereditary breast cancer. Pathobiology, prognosis and BRCA1 and BRCA2 linkage. Cancer. 1996, 77: 697-709. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W.CrossRefPubMed Marcus JN, Watson P, Page DL: Hereditary breast cancer. Pathobiology, prognosis and BRCA1 and BRCA2 linkage. Cancer. 1996, 77: 697-709. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W.CrossRefPubMed
22.
Zurück zum Zitat Lee JS, Wacholder S, Struewing JP, et al: Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 259-263. 10.1093/jnci/91.3.259.CrossRefPubMed Lee JS, Wacholder S, Struewing JP, et al: Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 259-263. 10.1093/jnci/91.3.259.CrossRefPubMed
23.
Zurück zum Zitat Frank TS, Manley SA, Olufunmilayo I, et al: Sequence analysis of BRCA1 and BRCA2: correlations of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed Frank TS, Manley SA, Olufunmilayo I, et al: Sequence analysis of BRCA1 and BRCA2: correlations of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed
24.
Zurück zum Zitat Chang-Claude J, Dong J, Schmidt S, et al: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet. 1998, 35: 116-121.CrossRefPubMedPubMedCentral Chang-Claude J, Dong J, Schmidt S, et al: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet. 1998, 35: 116-121.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed
26.
Zurück zum Zitat Lerman C, Narod S, Schulman K, et al: BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996, 275: 1885-1892. 10.1001/jama.275.24.1885.CrossRefPubMed Lerman C, Narod S, Schulman K, et al: BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996, 275: 1885-1892. 10.1001/jama.275.24.1885.CrossRefPubMed
27.
Zurück zum Zitat Chabner E, Nixon A, Gelman R, et al: Family history and treatment outcomes in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol . 1998, 16: 2045-2051.PubMed Chabner E, Nixon A, Gelman R, et al: Family history and treatment outcomes in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol . 1998, 16: 2045-2051.PubMed
29.
Zurück zum Zitat Tabár L, Larsson LG, Anderson I, et al: Breast-cancer screening with mamography in women aged 40-49 years. Int J Cancer. 1996, 68: 693-699. 10.1002/(SICI)1097-0215(19961211)68:6<693::AID-IJC1>3.3.CO;2-P.CrossRef Tabár L, Larsson LG, Anderson I, et al: Breast-cancer screening with mamography in women aged 40-49 years. Int J Cancer. 1996, 68: 693-699. 10.1002/(SICI)1097-0215(19961211)68:6<693::AID-IJC1>3.3.CO;2-P.CrossRef
30.
Zurück zum Zitat Dickersin K: Breast screening inwomen aged 40-49 years: what next?. Lancet. 1999, 353: 1896-1897. 10.1016/S0140-6736(99)90074-0.CrossRefPubMed Dickersin K: Breast screening inwomen aged 40-49 years: what next?. Lancet. 1999, 353: 1896-1897. 10.1016/S0140-6736(99)90074-0.CrossRefPubMed
31.
Zurück zum Zitat Lalloo F, Boggis CRM, Evans DGR, et al: Screening by mammography, women with a family history of breast cancer. Eur J Cancer. 1998, 34: 937-940. 10.1016/S0959-8049(98)00005-7.CrossRefPubMed Lalloo F, Boggis CRM, Evans DGR, et al: Screening by mammography, women with a family history of breast cancer. Eur J Cancer. 1998, 34: 937-940. 10.1016/S0959-8049(98)00005-7.CrossRefPubMed
32.
Zurück zum Zitat Möller P, Maehle L, Heimdal K, et al: Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. Breast. 1998, 7: 55-59. 10.1016/S0960-9776(98)90053-4.CrossRef Möller P, Maehle L, Heimdal K, et al: Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. Breast. 1998, 7: 55-59. 10.1016/S0960-9776(98)90053-4.CrossRef
33.
Zurück zum Zitat Kollias J, Sibbering DM, Blamey RW, et al: Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer. 1998, 34: 878-883. 10.1016/S0959-8049(97)00365-1.CrossRefPubMed Kollias J, Sibbering DM, Blamey RW, et al: Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer. 1998, 34: 878-883. 10.1016/S0959-8049(97)00365-1.CrossRefPubMed
34.
Zurück zum Zitat Forrest APM: . Breast Cancer Screening: Report to the Health Ministers of England, Wales, Scotland and Northern Ireland. London: HMSO. 1986 Forrest APM: . Breast Cancer Screening: Report to the Health Ministers of England, Wales, Scotland and Northern Ireland. London: HMSO. 1986
Metadaten
Titel
The pathology of familial breast cancer: Clinical and geneticcounselling implications of breast cancer pathology
verfasst von
Fiona Lalloo
D Gareth R Evans
Publikationsdatum
01.12.1999
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/1999
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr13

Weitere Artikel der Ausgabe 1/1999

Breast Cancer Research 1/1999 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.